Rosiglitazone reduces blood pressure in female Dahl salt-sensitive rats.
Postmenopausal women (PMW) are at greater risk for salt-sensitive hypertension and insulin resistance than premenopausal women. Peroxisome-proliferator-activated receptor-gamma (PPARgamma) agonists reduce blood pressure (BP) and insulin resistance in humans. As in PMW, ovariectomy (OVX) increases salt sensitivity of BP and body weight in Dahl salt-sensitive (DS) rats. This study addressed whether rosiglitazone (ROSI), a PPARgamma agonist, attenuates salt-sensitive hypertension in intact (INT) and OVX DS rats, and if so, whether insulin resistance, nitric oxide (NO), oxidative stress, and/or renal inflammation were contributing mediators. Telemetric BP was similar in OVX and INT on low salt diet (0.3% NaCl), but was higher in OVX than INT on high salt (8% NaCl). ROSI reduced BP in OVX and INT on both low and high salt diet, but only attenuated salt sensitivity of BP in OVX. Nitrate/nitrite excretion (NO(x); index of NO) was similar in INT and OVX on low salt diet, and ROSI increased NO(x) in both groups. High salt diet increased NO(x) in all groups but ROSI only increased NO(x) in OVX rats. OVX females exhibited insulin resistance, increases in body weight, plasma leptin, cholesterol, numbers of renal cortical macrophages, and renal MCP-1 and osteopontin mRNA expression compared to INT. ROSI reduced cholesterol and macrophage infiltration in OVX, but not INT. In summary, PPARgamma activation reduces BP in INT and OVX females, but attenuates the salt sensitivity of BP in OVX only, likely due to increases in NO and in part to reductions in renal resident macrophages and inflammation.
Sartori-Valinotti
Julio C
JC
Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216-4505, United States.
Venegas-Pont
Marcia R
MR
Lamarca
Babbette B
BB
Romero
Damian G
DG
Yanes
Licy L
LL
Racusen
Lorraine C
LC
Jones
Allison V
AV
Ryan
Michael J
MJ
Reckelhoff
Jane F
JF
D000419:Albuminuria / Q000150:complications; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D018932:Chemokine CCL2 / Q000235:genetics / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D004958:Estradiol / Q000097:blood; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D007150:Immunohistochemistry; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D020738:Leptin / Q000097:blood; D009566:Nitrates / Q000652:urine; D009573:Nitrites / Q000652:urine; D053495:Osteopontin / Q000235:genetics / Q000378:metabolism; D010052:Ovariectomy; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D020303:Rats, Inbred Dahl; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
D015415:Biomarkers; D001786:Blood Glucose; C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D007328:Insulin; D020738:Leptin; D009566:Nitrates; D009573:Nitrites; D012333:RNA, Messenger; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D053495:Osteopontin; D004958:Estradiol; D002784:Cholesterol